This project will promote online collaborations among clinicians involved in the care of patients with early-stage NSCLC. The digital curriculum will incorporate real-time activities; collaborative, small group discussions and tasks; self-study modules; and a social learning platform. ACCC is currently recruiting Group Leaders (3-4 hours time over 8 weeks; honorarium provided) and Group Participants (2.5 hours time over 8 weeks).
Credits Available: 1.0 AMA PRA Category 1 Credit(s)™️: 1.0 contact hour of continuing pharmacy education credit; 1.0 contact hour for nurses.
This enduring material was recorded from an interactive, virtual (live) summit to enhance coordination of patient care and gain deeper scientific knowledge, skills, and competence in biomarker testing practices, treatment selection, and management of adverse events in patients with advanced NSCLC.
Credits Available: This activity offers up to 4.5 hours of CME/CMLE credit.
December 2021 Content Update: This updated enduring web course, which offers CME, CNE, and CPE credit, is available for viewing only until January 29, 2022. Included in this course are data from the PEACE-1 phase 3 trial exploring triple therapy, ongoing trials in metastatic castration-sensitive prostate cancer, and quality of life studies on systemic therapies.
This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.
Credits Available: 1.0 AMA PRA Category 1 Credit(s)™: 1.0 contact hour of continuing pharmacy education credit; 1.0 contact hour for nurses.
Improve your knowledge of, confidence, and competence in the appropriate use of oral agents for patients with HR-positive, advanced, or metastatic breast cancer during the HOPA Satellite Symposium Pre-Conference, Oral Agents for Advanced Hormone Receptor Positive Breast Cancer, April 12 at 1:00 PM CDT. Hear from panelists as they discuss challenging cases of patients, their guidance on evidence-based treatment choices for patients in the various lines of treatment, and the management of treatment-related severe adverse events in these patients.
Walk away with strategies to manage acquisition of, adherence to, and treatment-related adverse events of oral drug-inclusive treatment regimens as part of a multidisciplinary team.
Credits Available: To view this session without claiming credit, please click here.
1.0 AMA PRA Category 1 Credit(s)™: 1.0 contact hour for nurses; 1.0 contact hour of continuing pharmacy education credit when the course is taken through the HOPA learning portal.
To claim continuing pharmacy education credit, enroll here.